Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:57:30.411Z.
Consensus retrieved: 2026-10-06T14:38:07.205Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:57:30.411Z.
Quote observation: 2026-10-06T15:32:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 733e4da94f9494cd21c7af02f5120fd8528014c079e3dffba0957966aae51245
Forward PE Ratio (N/A) = Dated Quote Price ($5.30) / Consensus Forward EPS ($-6.34)
FORWARD PE RATIO
N/A
NextCure, Inc.
Market Cap
$19.14M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| NextCure, Inc. (NXTC) | $19.14M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.86M | N/A |
| P3 Health Partners Inc. (PIII)vs › | $19.66M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.86M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $19.96M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.48M | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.92M | N/A |
| PAVmed Inc. (PAVM)vs › | $17.36M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.15M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $5.30, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-6.34 | $-6.52 – $-6.18 | 1 | n/m |
| 2027-12-31 | $-1.38 | $-1.38 – $-1.38 | 1 | n/m |
| 2028-12-31 | $-1.22 | $-1.22 – $-1.22 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
